Skip to main content

Table 1 Summary of available best evidence on serious upper gastrointestinal complications

From: Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk

Treatment Best evidence Patient years of exposure Number of events PUB(% per year)
Placebo Meta-analysis of rofecoxib trials [31] 112 3 2.68
Placebo Meta-analysis of celecoxib trials [28] 441 1 0.23
Celecoxib Meta-analysis of celecoxib trials [28] 7943 74 0.93
Etoricoxib Meta-analysis of etoricoxib trials [29] 4007 19 0.47
Lumiracoxib RCT [15] 6368 29 0.46
Rofecoxib Meta-analysis of rofecoxib trials [31,13] 8524 28 0.33
Valdecoxib Meta-analysis of valdecoxib trials [30] 1183 8 0.68
NSAID Meta-analysis of celecoxib trials [28] 5258 110 2.09
NSAID Meta-analysis of etoricoxib trials [29] 2230 23 1.03
NSAID RCT with lumiracoxib [15] 6845 83 1.21
NSAID Meta-analysis of rofecoxib trials [31,13] 5532 50 0.90
NSAID Meta-analysis of valdecoxib trials [30] 563 11 1.95
  1. PUB – perforations, ulcers, bleeds; RCT – randomised controlled trial